OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

2011 Program Project Development Grant Recipient – Weiping Zou

Weiping Zou, MD, PhD
University of Michigan, Ann Arbor
Understanding How Ovarian Cancer Stem Cells Play a Role in Disease Progression and Drug Resistance

Project Summary

Most women first diagnosed with ovarian cancer usually have advanced disease. While most of these patients will initially respond to surgery and chemotherapy, relapse with drug-resistant cancer usually occurs and the women die. In his project, Dr. Zou will use an animal model to study various types of ovarian cancer cells, including the cancer stem cell, which is believed to play a role in cancer development, cancer metastasis and chemotherapy resistance. He will also study the role immune cells and other cells in the tumor microenvironment play in facilitating cancer stem cell growth and in chemotherapy resistance. His findings should lead to a greater understanding of the defects in the molecular pathways involved in disease progression and drug resistance.

Bio

Weiping Zou M.D., Ph.D. is a Professor of Surgery, Immunology and Biology, Director of Translational Research and Co-Director, Immune Monitoring Core at the University of Michigan in Ann Arbor, Michigan. He received his Bachelor and Medical degrees from Tongji Medical School and his doctoral degree from University of Paris. He has received numerous honors and awards including The Charles B. Henriques Award for Excellence in Research, Tulane Outstanding and Research Excellence, and the Presidential Award at Tulane. Dr. Zou’s research interest is in tumor immunopathology and therapy, with an emphasis on the roles of immune cells, and the interaction between immune cells and cancer stem cells in tumor immune immunity and therapy.